Supriya Lifescience Q4 FY26: Revenue up 50% YoY

Key takeaways from the latest numbers

Supriya Lifescience Ltd has reported a strong set of top-line growth data points across FY26 and recent quarters, signalling better execution after a softer patch earlier in the year. FY26 revenue grew 19% year-on-year (YoY) to ₹828 crore. Q4 revenue surged 50% YoY to ₹277 crore, pointing to momentum in deliveries and demand conversion.

The picture on profitability is positive but not uniform across time periods highlighted in the data. While net profit growth has been strong in the latest referenced periods, operating margin commentary suggests costs and mix remain variables to track. For investors in the Pharma and API space, the upcoming Q4 FY26 result cycle and FY27 guidance are positioned as key catalysts.

FY26 revenue rises to ₹828 crore, Q4 jumps to ₹277 crore

The FY26 revenue figure of ₹828 crore, up 19% YoY, gives a clear benchmark for the company’s growth trajectory. The Q4 revenue print of ₹277 crore, up 50% YoY, is a sharper acceleration than the full-year rate, and is being read as evidence of execution momentum.

In the context of APIs and pharma intermediates, quarterly swings can reflect shipment timing, product mix, and ramp-ups at facilities. The data provided frames Q4 as a strong quarter on revenue, which becomes important when placed alongside commentary on margin movement. Investors typically weigh whether a faster-growing quarter is also a high-quality quarter in terms of operating leverage.

Q2 FY26 signals recovery, but margin pressure remains

The latest referenced Q2 FY26 results indicate a rebound in profitability and revenue. Net profit increased 44.97% while revenue rose 37.75%, signalling broad-based improvement versus the comparable period. At the same time, the operating margin is stated to have declined, creating a mixed assessment of the quarter.

This combination often matters for market perception. Strong revenue growth can lift earnings, but a falling operating margin can raise questions on cost inflation, pricing, or product mix. With only directional margin commentary available here, the key point for investors is that profitability is improving, but pressure points have not fully faded.

Q4 profit grows to ₹74.23 crore, strong sequential jump too

On the profit line, the data indicates Supriya Lifescience’s net profit rose 47.34% YoY to ₹74.23 crore in Q4 2025-2026. Sequentially, net profits jumped 49.42% over the prior three months.

Both the YoY and quarter-on-quarter growth rates are sizeable, and they align with the narrative of stronger execution. For investors, this is also a useful cross-check against the margin concerns mentioned for Q2 FY26. It suggests that even with margin variability across periods, the company has delivered meaningful earnings growth in the latest referenced quarter.

Q1 FY26 was softer on revenue and margins

The dataset also includes Q1 FY26 numbers that show a weaker starting point for the year. Revenue declined 9.7% YoY to ₹145.07 crore from ₹160.63 crore in Q1 FY25. EBITDA for Q1 FY26 was ₹51.70 crore with an EBITDA margin of 35.6%, compared with ₹62.54 crore and a 38.9% margin in Q1 FY25.

Profit after tax (PAT) in Q1 FY26 was ₹34.79 crore versus ₹44.64 crore in Q1 FY25, while PAT margin came in at 24.0% versus 27.8%. This helps explain why later-quarter acceleration is being watched closely. It also frames the year as one where the second half performance and the timing of operational milestones could drive the outcome.

What management commentary highlights: Ambernath and launches

Alongside the Q1 FY26 data, the note points to stable margins near 36% despite the revenue dip, supported by improved backwards integration and a higher contribution from regulated markets. It also mentions the Ambernath site progressing towards commercial production in Q4.

A pipeline of 3 to 4 product launches in FY26 and healthy demand across key therapeutic areas are cited as supports for a recovery in the second half after delays in the first half. The company states it remains on track to deliver around 20% growth and reach ₹1,000 crore revenue by FY27. These are specific operational and growth markers that investors commonly map to future revenue visibility.

Street expectations for Q4 FY26: ₹350–380 crore revenue, PAT ₹96–110 crore

Analyst estimates for Q4 FY26 set expectations for revenue at ₹350–380 crore. Profit expectations are stated as PAT of ₹96–110 crore, with EBITDA margin projections of 38–41%.

Separately, Supriya Lifescience is described as entering Q4 FY26 with expectations of 10–14% YoY revenue growth. The Q4 FY26 results (expected in May 2026) are framed as a key event for Pharma and API sector investors. Another point emphasised is that FY27 guidance will be a critical post-results catalyst.

Stock movement and key price levels investors are watching

As of 26-May, Supriya Lifescience Ltd’s stock price is stated at ₹779.95, up 1.81%. The move is attributed to strong performance metrics over various periods, positive technical indicators, and increasing institutional investor confidence, even as delivery volume is said to have declined recently.

The stock is also described as trading at ₹580 in early April 2026, compared with a 52-week high of ₹780 and a 52-week low of ₹440. This sets the context for how the market is pricing the company going into the next results milestone, and how sharply sentiment can shift within the yearly range.

Broker and platform views: targets, ratings, and “Hold” stance

Heading into Q4 FY26, broker calls cited include: MOFSL (Buy, target ₹750), YES Securities (Buy, target ₹730), JM Financial (Add, target ₹700), and Emkay (Buy, target ₹710). The same dataset notes analyst targets ranging from ₹710 to ₹750 when the stock was referenced at ₹580.

MarketsMOJO’s rating for Supriya Lifescience is “Hold”, indicating a neutral stance. The rating was adjusted on 20 Oct 2025 from “Sell” to “Hold”, and the Mojo Score is stated as 60.0, corresponding to the “Hold” grade. As of 01 February 2026, the stock is described as having good quality fundamentals, an expensive valuation, flat financial trends, and a mildly bullish technical stance.

Key facts table

Why this matters for Pharma and API investors

The combined set of inputs creates a clear investor checklist. One, FY26 revenue growth and the sharp Q4 revenue rise show momentum. Two, profitability has improved strongly in the latest referenced quarter, but the mention of operating margin decline in Q2 FY26 keeps focus on sustainability.

Three, the market is treating the expected May 2026 Q4 FY26 results and subsequent FY27 guidance as decision points. And four, ratings are not uniform across platforms, with broker targets pointing higher in some cases, while MarketsMOJO maintains a neutral “Hold” view due to valuation and trend considerations.

Conclusion

Supriya Lifescience has reported strong FY26 revenue growth to ₹828 crore and a sharp Q4 revenue increase to ₹277 crore, alongside a Q4 net profit of ₹74.23 crore. At the same time, operating margin pressure flagged in Q2 FY26 and valuation-related caution keep the assessment balanced.

The next concrete trigger is the expected Q4 FY26 results in May 2026, where analyst estimates for revenue (₹350–380 crore), PAT (₹96–110 crore), and EBITDA margin (38–41%) will shape how investors interpret the company’s FY27 guidance.